MAP2K1 and thyroid cancer: In addition, our study demonstrates that BIM is a potential functional biomarker of response that can be tested in thyroid cancer and other tumors in response to Src and MEK1/2 inhibition, including non-small cell lung, breast, and ovarian cancers, which are dependent on cooperative Src and MAPK signaling [32,33,34].